Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601941 | 0.84 | CA1 (0.47) | TSHRALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL3607988 | 0.81 | MAPT (0.51) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL12487393 | 0.81 | MAPT (0.42) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL3611844 | 0.79 | ALDH1A1 (0.51) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL3602828 | 0.79 | PARP15 (0.47) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL644054 | 0.79 | CA1 (0.48) | TSHRALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL3603132 | 0.78 | GCK (0.48) | — | |
| SCHEMBL3600051 | 0.78 | SMN1; SMN2 (0.55) | ALDH1A1MAPTSMN1; SMN2HPGDNPC1 | |
| SCHEMBL3604464 | 0.77 | MAPT (0.38) | TSHRALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL3609653 | 0.76 | MAPT (0.38) | TSHRMAPTSMN1; SMN2KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754743-B2 | Heteroarylcarbamoylbenzene derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20090018056-A1 | Heteroarylcarbamoylbenzene derivatives | MSD K.K. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-7432287-B2 | Heteroarylcarbamoylbenzene derivative | BANYU PHARMECEUTICAL CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | MSD K.K. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1600442-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018056-A1 | Heteroarylcarbamoylbenzene derivatives | GCK, GCKR, KHK | TSHR 2079/4885ALDH1A1 707/4885MAPT 4717/4885 |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | GCK, GCKR, GALK1 | TSHR 3647/4885ALDH1A1 902/4885MAPT 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.